There are gifts, and then there are gifts, the ones inventive enough to surprise and delight the recipient. Some are fun; ...
Medpage Today on MSN
WIC Telehealth Program Improved Diet, Had Modest Impact on Weight Gain in Pregnancy
Recommendations for optimal gestational weight gain are different depending on a woman's body mass index (BMI), ranging from ...
The MarketWatch News Department was not involved in the creation of this content.-- Third quarter 2025 revenue of $9.5 million, up 10% year-over-year -- Amended credit agreement w ...
Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with ...
Q3 2025 Earnings Call Transcript November 13, 2025 BioHarvest Sciences Inc. Common Stock reports earnings inline with expectations. Reported EPS is $-0.14 EPS, expectations were $-0.14. Operator: ...
Onyx Gold Commences 50,000 M Phase Three Drill Program And Adds Third Rig At The Munro-Croesus Gold Project, Ontario.
Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsPhillip Chan - CEO & DirectorPeter Mariani ...
Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026New preclinical data demonstrated SIL204’s ...
Net Loss: $3.24 million attributable to Cycurion for the third quarter 2025 ($1.59 loss per basic share); $18.78 million for the nine months ended September 30, 2025 ($14.82 loss per basic share), ...
Q1 2026 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsNicole JosephLeeAnn Rohmann - CEO, Chairman ...
Everyday Health on MSN
Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound
Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone amylin that slows digestion and reduces hunger.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback